XBIO

Xenetic Biosciences, Inc. XBIO

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $7.6M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Revenue

$660.6K

Quarter to Jun 30

Net income

$-929.7K

Quarter to Jun 30

Operating margin

-147.1%

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$442.8K total
RENAISSANCE TECHNOLOGIES LLC
$341.8K-14.6%
GEODE CAPITAL MANAGEMENT, LLC
$50.7K-18.7%
VANGUARD CAPITAL MANAGEMENT LLC
$36.9K+88.4%
JTC Employer Solutions Trusteee Ltd
$8.0K0.0%
SBI Securities Co., Ltd.
$2.9KNew
Tower Research Capital LLC (TRC)
$2.0K-13.6%
MORGAN STANLEY
$437New
Darwin Wealth Management, LLC
$50.0%
See all 8 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Operating Margin

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/XBIO

Earnings Per Share

13fpro.ai/company/XBIO

Loading ratio trend…

XBIO key financials by period

Reported revenue, net income and operating margin by fiscal year, from Xenetic Biosciences, Inc.'s annual filings on SEC EDGAR.

Xenetic Biosciences, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$3.0M$-2.7M-95.2%
FY 2024$2.5M$-4.0M-168.2%
FY 2023$2.5M$-4.1M-177.8%
FY 2022$1.7M$-6.6M—
FY 2021$1.2M$-5.6M—
FY 2020$436.9K$-10.9M—
Source: XBIO filings on SEC EDGAR →

XBIO insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Xenetic Biosciences, Inc. (XBIO): stock profile, AI score and financials

Xenetic Biosciences, Inc. (XBIO) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. XBIO is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $7.6m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Xenetic Biosciences, Inc. reports quarterly revenue of $660.6K, net income of $-929.7K, an operating margin of -147.1%. Top institutional holders of XBIO by reported 13-F value include RENAISSANCE TECHNOLOGIES, GEODE CAPITAL MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. XBIO trades on the Nasdaq exchange and files with the SEC under CIK 1534525. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate XBIO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Xenetic Biosciences, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1534525 →